Insight

Nicola Fusco: The assessment of PDL1 Combined Positive Score (CPS)≥10 in metastatic triple-negative breast cancer.

Photo from Nicola Fusco/LinkedIn

Aug 18, 2023, 04:56

Nicola Fusco: The assessment of PDL1 Combined Positive Score (CPS)≥10 in metastatic triple-negative breast cancer.

Nicola Fusco, an Associate Professor at the Department of Oncology and Hemato-Oncology at the University of Milan, shared on LinkedIn:

”We’re thrilled to share our latest publication titled “Advancing the PD-L1 CPS test in metastatic TNBC: Insights from pathologists and findings from a nationwide survey,” now available in Critical Reviews in Oncology Hematology Elsevier at the following link: https://lnkd.in/ezkTJFyc.

In the dynamic landscape of breast cancer precision pathology, our nationwide Italian effort delves into a crucial topic: the assessment of PDL1Combined Positive Score (CPS)≥10 in metastatic triple-negative breast cancer (mTNBC).
Pathologists play a pivotal role as they navigate the novel analysis that CPS testing presents. The diversity in PD-L1 expression within mTNBC adds further challenges to the assessment process, while the absence of standardized assays and staining platforms amplifies the intricacy. The well-established IHC 22C3 and the SP263 assays both serve as validated options for CPS assessment. However, the choice of assay-platform, staining conditions, and scoring methods can significantly influence testing outcomes.

Our consensus paper brings together insights from pathologists, offering a comprehensive discussion on the nuances of PD-L1 CPS testing in mTNBC. Through shared experiences and expertise, practical recommendations are provided to guide pathologists through the complexities of this crucial analysis.
Furthermore, we are delighted to present findings from a nationwide Italian survey that sheds light on the current state-of-the-art in PD-L1 CPS testing in mTNBC. By collating data from across our nation, we aim to contribute to the advancement of this field and foster a deeper understanding of its challenges and opportunities.

This publication marks another step forward in our collective journey to enhance treatment strategies through breast cancer pathology.”

Source: Nicola Fusco/LinkedIn